Technology-enhanced, culturally-informed primary care results in sustained improvements in biomarkers for Indigenous patients with type 2 diabetes - a pilot study.
Lynne M Chepulis, Rebekah Crosswell, Suzanne Moorhouse, Helen Morton, Michael Oehley, Ryan Paul, Hamish Crocket
{"title":"Technology-enhanced, culturally-informed primary care results in sustained improvements in biomarkers for Indigenous patients with type 2 diabetes - a pilot study.","authors":"Lynne M Chepulis, Rebekah Crosswell, Suzanne Moorhouse, Helen Morton, Michael Oehley, Ryan Paul, Hamish Crocket","doi":"10.1071/HC24056","DOIUrl":null,"url":null,"abstract":"<p><p>Introduction Type 2 diabetes disproportionately affects Indigenous Māori in New Zealand. The reasons for this are multifactorial but include a history of colonialism, barriers to health care access and a lack of culturally appropriate interactions/relationships with health care providers. There is currently a need to develop models of health care delivery that are tailored to the needs of this population. Aim This pilot study evaluates the use of technology, education and culturally-informed wrap-around care (including medication optimisation) to improve type 2 diabetes biomarkers and self-management in a high-needs, majority Indigenous population. Methods Twenty-three participants with HbA1c >80mmol/L received 2-4weeks of continuous glucose monitor (CGM) wear at baseline and at 3months alongside culturally-informed type 2 diabetes education and clinical care. Clinical biomarkers and psychometric measures were recorded at 0, 3, 6 and 12months and 0 and 3months respectively. Medication changes were recorded throughout the study. Results Mean (± s.d.) HbA1c significantly decreased from 93.4±15.7mmol/mol at baseline to 76.5±14.8mmol/mol at 3months, with reductions maintained at 6 and 12months by approximately three-quarters of participants (all P Discussion CGM informed, culturally-appropriate care has the potential to lead to sustained improvements in glycaemia in high-risk, Indigenous populations managed in primary care.</p>","PeriodicalId":16855,"journal":{"name":"Journal of primary health care","volume":"17 1","pages":"83-87"},"PeriodicalIF":1.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of primary health care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1071/HC24056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction Type 2 diabetes disproportionately affects Indigenous Māori in New Zealand. The reasons for this are multifactorial but include a history of colonialism, barriers to health care access and a lack of culturally appropriate interactions/relationships with health care providers. There is currently a need to develop models of health care delivery that are tailored to the needs of this population. Aim This pilot study evaluates the use of technology, education and culturally-informed wrap-around care (including medication optimisation) to improve type 2 diabetes biomarkers and self-management in a high-needs, majority Indigenous population. Methods Twenty-three participants with HbA1c >80mmol/L received 2-4weeks of continuous glucose monitor (CGM) wear at baseline and at 3months alongside culturally-informed type 2 diabetes education and clinical care. Clinical biomarkers and psychometric measures were recorded at 0, 3, 6 and 12months and 0 and 3months respectively. Medication changes were recorded throughout the study. Results Mean (± s.d.) HbA1c significantly decreased from 93.4±15.7mmol/mol at baseline to 76.5±14.8mmol/mol at 3months, with reductions maintained at 6 and 12months by approximately three-quarters of participants (all P Discussion CGM informed, culturally-appropriate care has the potential to lead to sustained improvements in glycaemia in high-risk, Indigenous populations managed in primary care.